 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Praxis Precision Medicines trading halted, news pending

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX  Free Report) shares are set to reverse split on the morning of Wednesday, November 29th. The 1-15 reverse split was announced on Wednesday...

Praxis Precision Medicines Stock Scheduled to Reverse Split on Wednesday, November 29th (NASDAQ:PRAX)

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Praxis Precision Medicines, Inc. (NASDAQ:PRAX  Free Report)  Equities researchers at HC Wainwright lifted their FY2023 EPS estimates for Praxis Precision Medicines in a research report...

HC Wainwright Weighs in on Praxis Precision Medicines, Inc.'s FY2023 Earnings (NASDAQ:PRAX)

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines (PRAX Research Report) today and set a price target of...

Praxis Precision Medicines: A Promising Buy Recommendation Based on Unique Approach and Competitive Edge in Focal Epilepsy Treatment

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Company's Cash Position Supports Runway into Q1 2025, R&D Expenses Decrease by 43.5% Year-Over-YearRelated Stocks: PRAX...

Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Watchers	908
52-Wk Low	$11.85
52-Wk High	$78.75

Market Cap	$155.97M
Volume (M)	64,807.00
52-Wk High	$78.75
52-Wk Low	$11.85

PRAX Praxis Precision Medicines Inc

About

Feed

News

Sentiment

Earnings

Fundamentals